US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Cellectis Romainville

4.40

0.0000

Volume:- -

Turnover:- -

Market Cap:440.41M

PE:-4.25

High:4.40

Open:4.40

Low:4.40

Close:4.40

52wk High:5.04

52wk Low:1.25

Shares:100.09M

Float Shares:71.46M

Volume Ratio:0.02

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.0354

EPS(LYR):-1.7726

ROE:-30.75%

ROA:-4.47%

PB:4.38

PE(LYR):-2.48

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Cellectis Romainville

Exchange:

PINK LIMITED

Establishment Date:

1999

Employees:

219

Office Location:

8, rue de la Croix Jarry,Paris,Ile-de-France,France

Website:

http://www.cellectis.com

Zip Code:

75013

Phone:

33 1 81 69 16 00

Fax:

- -

Introduction:

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CMVLF/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CMVLF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CMVLF\",,,,,undefined,":{"symbol":"CMVLF","market":"US","secType":"STK","nameCN":"Cellectis Romainville","latestPrice":4.4,"timestamp":1771621200000,"preClose":4.4,"halted":0,"volume":0,"delay":15,"changeRate":0,"floatShares":71463341,"shares":100093873,"eps":-1.035365,"marketStatus":"Market Closed","change":0,"latestTime":"02-20 16:00:00 EST Delay","open":4.4,"high":4.4,"low":4.4,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-1.035365,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"PINK LIMITED","adjPreClose":4.4,"volumeRatio":0.018435863319847208},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CMVLF\",,,,,undefined,":{"symbol":"CMVLF","floatShares":71463341,"roa":"-4.47%","roe":"-30.75%","lyrEps":-1.772566,"volumeRatio":0.018435863319847208,"shares":100093873,"dividePrice":0,"high":4.4,"amplitude":0,"preClose":4.4,"low":4.4,"week52Low":1.25,"pbRate":"4.38","psRate":"5.34","week52High":5.04,"institutionHeld":0,"latestPrice":4.4,"eps":-1.035365,"divideRate":0,"volume":0,"delay":15,"ttmEps":-1.035365,"open":4.4,"prevYearClose":4.4,"prevWeekClose":4.4,"prevMonthClose":4.4,"prevQuarterClose":4.4,"fiveDayClose":4.4,"twentyDayClose":4.4,"sixtyDayClose":4.5},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CMVLF\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-05-28","symbol":"CMVLF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1716868800000,"reportTimeType":"","actualEps":null},{"date":"2024-05-09","symbol":"CMVLF","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1715241600000,"name":null,"time":"","dateTimestamp":1715227200000,"actualEps":null},{"date":"2022-11-03","symbol":"CMVLF","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1667505600000,"name":null,"time":"Post Market","dateTimestamp":1667448000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CMVLF\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CMVLF\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.4,"hold":0.2,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.4,"analysts":5,"updateTime":1754456400000},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":1216695,"yearFounded":1999,"employeeNum":219,"address":"8, rue de la Croix Jarry,Paris,Ile-de-France,France","zipCode":"75013","officePhone":"33 1 81 69 16 00"},"stockCompanyDetail":{"websiteUrl":"http://www.cellectis.com","stockEarnings":[{"period":"1week","weight":-0.085},{"period":"1month","weight":-0.275},{"period":"3month","weight":-0.44},{"period":"6month","weight":-0.5556},{"period":"1year","weight":-0.6486},{"period":"ytd","weight":-0.4278}],"description":"Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.","exchange":"PINK LIMITED","name":"Cellectis Romainville","nameEN":"Cellectis Romainville"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"CMVLF\",market:\"US\",,,undefined,":null}}